Industry Insight
Discovery Technology
Analytical Laboratory Technology
Delivery Systems
Ingredients, Formulation and Finishing
View our other publications with free access to extensive archives


 26th June 2014 PAREXEL

Parexel Cuts Clinical Trial Start-Up Time for Sponsors by Weeks with New Version of Industry-Leading Clinphone® RTSM Services

Latest RTSM technology features standardized study components for faster implementation and greater design flexibility

PAREXEL International (NASDAQ: PRXL), a leading global biopharmaceutical services organisation, today announced the launch of a new version of its industry standard ClinPhone® RTSM services designed to help clients start clinical trials more quickly. The leading edge randomisation and trial supply management (RTSM) solution has been used in more than 3,000 studies involving over 400,000 sites and two million patients since 1993. Developed by PAREXEL Informatics, it is a key component of the Perceptive MyTrials® platform, an integrated suite of applications for managing clinical trials.

Biopharmaceutical companies are increasingly seeking to make drug development more efficient without compromising patient safety or data quality. Efficiency is particularly critical at the start of clinical trials, when clients must simultaneously initiate a broad range of important activities such as patient screening, enrollment and randomisation, as well as drug dispensation and supply distribution.

Addressing these issues, ClinPhone® RTSM can be more rapidly implemented using pre-built, interactive web modules for patient, supply and site activities common to every study. PAREXEL Informatics can also streamline system review and approval for clients via an efficient visual design approach.

“Based upon our experience across thousands of studies, we have identified ways to standardise common functionality for patient screening, medication re-supply and other fundamental study activities,” said Xavier Flinois, President of PAREXEL Informatics. “Our customers can simplify trial management activities, and ultimately start their trials more quickly, using our powerful and flexible RTSM technology.”

“There is a growing need for faster, more efficient clinical trials, yet conducting them has become increasingly complex,” said Mark A. Goldberg, M.D., President and Chief Operating Officer, PAREXEL. “Trial success often hinges on start-up speed and effectiveness. At PAREXEL, we view drug development as a journey, and have made considerable investments in developing cutting-edge technology to help simplify it from beginning to end.”

ClinPhone® RTSM is available through the Perceptive MyTrials® platform and as a standalone solution. ClinPhone® RTSM and the Perceptive MyTrials® platform are also available through the Perceptive® Partner Program.

About PAREXEL International

PAREXEL International Corporation is a leading global biopharmaceutical services organisation, providing a broad range of knowledge-based contract research, consulting, medical communications, and technology solutions and services to the worldwide pharmaceutical, biotechnology and medical device industries. Committed to providing solutions that expedite time-to-market and peak-market penetration, PAREXEL has developed significant expertise across the development and commercialization continuum, from drug development and regulatory consulting to clinical pharmacology, clinical trials management, medical education and reimbursement. PAREXEL Informatics provides advanced technology solutions, including medical imaging, to facilitate the clinical development process. Headquartered near Boston, Massachusetts, PAREXEL operates in 75 locations in 50 countries around the world, and has approximately 15,335 employees. For more information about PAREXEL International visit

PAREXEL, Perceptive, Perceptive MyTrials, ClinPhone, and “Your Journey. Our Mission.” are trademarks or registered trademarks of PAREXEL International Corporation or its affiliates.

This release contains “forward-looking” statements regarding future results and events. For this purpose, any statements contained herein that are not statements of historical fact may be deemed forward-looking statements. Without limiting the foregoing, the words “believes,” “anticipates,” “plans,” “expects,” “intends,” “appears,” “estimates,” “projects,” “will,” “would,” “could,” “should,” “targets,” and similar expressions are also intended to identify forward-looking statements. The forward-looking statements in this release involve a number of risks and uncertainties. The Company’s actual future results may differ significantly from the results discussed in the forward-looking statements contained in this release. Important factors that might cause such a difference include, but are not limited to, risks associated with: actual operating performance; actual expense savings and other operating improvements resulting from recent and anticipated restructurings; the loss, modification, or delay of contracts which would, among other things, adversely impact the Company’s recognition of revenue included in backlog; the Company’s dependence on certain industries and clients; the Company’s ability to win new business, manage growth and costs, and attract and retain employees; the Company’s ability to complete additional acquisitions, and to integrate newly acquired businesses including the recent acquisitions of LIQUENT, Inc. and HERON Group Ltd., Inc., or enter into new lines of business; the impact on the Company’s business of government regulation of the drug, medical device and biotechnology industry; consolidation within the pharmaceutical industry and competition within the biopharmaceutical services industry; the potential for significant liability to clients and third parties; the potential adverse impact of health care reform; and the effects of exchange rate fluctuations and other international economic, political, and other risks. Such factors and others are discussed more fully in the section entitled “Risk Factors” of the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2014 as filed with the Securities and Exchange Commission (SEC) on May 2, 2014, which “Risk Factors” discussion is incorporated by reference in this press release. The Company specifically disclaims any obligation to update these forward-looking statements in the future. These forward-looking statements should not be relied upon as representing the Company’s estimates or views as of any date subsequent to the date of this press release.


Advair,Flovent,VentolinSymbicort,Serevent,FlonaseAstelin Rhinocort
IPT © 2021 Innovations in Pharmaceutical Technology | Terms and Conditions | | UK Contacts |
Providing a platform of communication on new ideas, developments and innovations | UK Tel No. +44 20 77243456 | Back to top of page |